Evidence map›Paper›PMID 24858205›Full record

ArticleCarcinogenesis2014

Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers.

Tiffany A Wallace, Ronan F Downey, Caleb J Seufert, Aaron Schetter, Tiffany H Dorsey, Carol A Johnson, Radoslav Goldman, Christopher A Loffredo, Peisha Yan, Francis J Sullivan and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Carcinogenesis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
9.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Human Endogenous Retroviruses in Diseases.Sub-cellular biochemistry · 2023
    Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Tiffany A WallaceLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA, Prostate Cancer Institute, Biosciences Research Building, National University of Ireland Galway, Dangan, Corrib Village, Galway, Ireland, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057-1465, USA, Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Radiation Oncology, Galway University Hospital, Galway, Ireland and Viral Oncology, Center for Cancer and Metabolism, Stanford Research Institute International, Menlo Park, CA 94025, USA.
Ronan F DowneyProstate Cancer Institute, Biosciences Research Building, National University of Ireland Galway, Dangan, Corrib Village, Galway, Ireland.
Caleb J SeufertLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA, Prostate Cancer Institute, Biosciences Research Building, National University of Ireland Galway, Dangan, Corrib Village, Galway, Ireland, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057-1465, USA, Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Radiation Oncology, Galway University Hospital, Galway, Ireland and Viral Oncology, Center for Cancer and Metabolism, Stanford Research Institute International, Menlo Park, CA 94025, USA.
Aaron SchetterLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA, Prostate Cancer Institute, Biosciences Research Building, National University of Ireland Galway, Dangan, Corrib Village, Galway, Ireland, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057-1465, USA, Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Radiation Oncology, Galway University Hospital, Galway, Ireland and Viral Oncology, Center for Cancer and Metabolism, Stanford Research Institute International, Menlo Park, CA 94025, USA.
Tiffany H DorseyLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA, Prostate Cancer Institute, Biosciences Research Building, National University of Ireland Galway, Dangan, Corrib Village, Galway, Ireland, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057-1465, USA, Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Radiation Oncology, Galway University Hospital, Galway, Ireland and Viral Oncology, Center for Cancer and Metabolism, Stanford Research Institute International, Menlo Park, CA 94025, USA.
Carol A JohnsonProstate Cancer Institute, Biosciences Research Building, National University of Ireland Galway, Dangan, Corrib Village, Galway, Ireland.
Radoslav GoldmanDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057-1465, USA.
Christopher A LoffredoDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057-1465, USA.
Peisha YanDepartment of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Francis J SullivanProstate Cancer Institute, Biosciences Research Building, National University of Ireland Galway, Dangan, Corrib Village, Galway, Ireland, Department of Radiation Oncology, Galway University Hospital, Galway, Ireland and.
Francis J GilesProstate Cancer Institute, Biosciences Research Building, National University of Ireland Galway, Dangan, Corrib Village, Galway, Ireland.
Feng Wang-JohanningViral Oncology, Center for Cancer and Metabolism, Stanford Research Institute International, Menlo Park, CA 94025, USA.
Stefan AmbsLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA, Prostate Cancer Institute, Biosciences Research Building, National University of Ireland Galway, Dangan, Corrib Village, Galway, Ireland, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057-1465, USA, Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Radiation Oncology, Galway University Hospital, Galway, Ireland and Viral Oncology, Center for Cancer and Metabolism, Stanford Research Institute International, Menlo Park, CA 94025, USA.
Sharon A GlynnProstate Cancer Institute, Biosciences Research Building, National University of Ireland Galway, Dangan, Corrib Village, Galway, Ireland, sharon.glynn@nuigalway.ie.
National Institutes of Health · USOllscoil na Gaillimhe – University of Galway · IEGeorgetown University · USSRI International · USThe University of Texas Health Science Center at Houston · US

Funding

Maryland Prostate Cancer Case-Control StudyZIABC010499 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AMBS, STEFAN · 2009 to 2025
$11.4M
The Molecular Profile of Prostate Tumors in African-American MenZIABC010624 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AMBS, STEFAN · 2009 to 2025
$8.0M
Basic Cancer Research in Cancer Health DisparitiesU01CA171146 · NCI · GEORGETOWN UNIVERSITY · PI GOLDMAN, RADOSLAV · 2012 to 2016
$1.5M
Intramural NIH HHSNCI NIH HHS U01 CA171146NCI NIH HHS U01CA171146
6 · The paper itself

Abstract

Aberrant expression of subgroup k human endogenous retroviruses (HERV-K) has been observed in prostate cancer. This subgroup is unique because it encodes sequences in the human genome containing open reading frames for near intact retroviruses. We hypothesized that HERV-K reactivation could serve as a non-invasive early disease detection marker for prostate cancer. We evaluated HERV-K gag messenger RNA (mRNA) expression in blood samples of African-American and European-American men using a case-control design via quantitative real-time PCR. Additionally, we examined HERV-K envelope protein expression in prostate tumors by immunohistochemistry. HERV-K envelope protein was commonly upregulated in prostate tumors, but more so in tumors of African-American than European-American patients (61% versus 40%, P < 0.01). Examining HERV-K gag expression in peripheral blood mononuclear cells (PBMC) from 294 cases and 135 healthy men, we found that the abundance of HERV-K gag message was significantly higher in cases than controls and was associated with increased plasma interferon-γ. Men with gag expression in the highest quartile had >12-fold increased odds {odds ratio = 12.87 [95% confidence interval 6.3-26.25]} of being diagnosed with prostate cancer than those in the lowest quartile. Moreover, our results showed that HERV-K expression may perform better as a disease biomarker in older than younger men (whereas the sensitivity of prostate-specific antigen (PSA) testing decreases with age) and in men with a smoking history compared with never smokers. Combining non-invasive HERV-K testing with PSA testing may improve the efficacy of prostate cancer detection specifically among older men and smokers who tend to develop a more aggressive disease.

Indexed as

AdenocarcinomaChemokine CXCL10Endogenous RetrovirusesGene ExpressionGene Products, gagHumansInterferon-gammaLeukocytes, MononuclearMaleProstatic NeoplasmsRisk FactorsRNA, MessengerSmokingChemokine CXCL10CXCL10 protein, humanGene Products, gagInterferon-gammaRNA, Messenger

Identifiers

PMID24858205
PMCPMC4146419
OpenAlexW2101538344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.